Nimesh Dayal, MD
Rheumatology · Ocoee, FLNPI 1215145636
Payments from drug & device makers
Across 2,141 payments — averaging $191.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$302K
- Eli Lilly$34K
- Novartis$17K
- Pfizer$12K
- Amgen$8K
- UCB, Inc.$8K
- plus $29K from 29 others
What the payments were for
- Consulting fees$25,3967%
- Speaking & faculty fees$239,83867%
- Travel & lodging$55,67516%
- Food & beverage$36,87110%
- Education$6090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 567 | $302,009 |
| Eli Lilly | 2 | $33,584 |
| Novartis | 85 | $16,941 |
| Pfizer | 162 | $12,287 |
| Amgen(2 entities) | 512 | $8,024 |
| UCB, Inc. | 227 | $7,751 |
| Johnson & Johnson(2 entities) | 152 | $7,554 |
| UCB SA | 4 | $6,897 |
| AstraZeneca(2 entities) | 58 | $3,227 |
| Sobi, Inc | 17 | $2,388 |
| Janssen Scientific Affairs, LLC | 9 | $1,584 |
| Sanofi | 48 | $1,435 |
| GSK | 61 | $1,059 |
| Lilly USA, LLC | 51 | $1,004 |
| E.r. Squibb & Sons, L.L.C. | 39 | $628 |
| Aurinia Pharma U.S., Inc. | 19 | $427 |
| Genentech USA, Inc. | 32 | $364 |
| Boehringer Ingelheim | 16 | $342 |
| Radius Health, Inc. | 14 | $309 |
| Bristol Myers Squibb | 17 | $269 |
| Mallinckrodt Hospital Products Inc. | 8 | $257 |
| Davol Inc. | 2 | $205 |
| Sanofi-aventis U.S. LLC | 3 | $199 |
| Mallinckrodt Enterprises LLC | 10 | $196 |
| Gilead | 3 | $149 |
| Sandoz | 6 | $121 |
| Organon | 4 | $89 |
| Fresenius Kabi USA, LLC | 3 | $68 |
| Kyowa Kirin, Inc. | 3 | $52 |
| Fidia Pharma USA Inc. | 2 | $37 |
| Tersera Therapeutics LLC | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$409,551 in reported general payments places this provider in the 85th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 52 | $417,898 |
| Enbrel SureclickEtanercept | 32 | $270,709 |
| KevzaraSarilumab | 33 | $150,910 |
| Enbrel MiniEtanercept | 16 | $149,458 |
| Orencia ClickjectAbatacept | 20 | $116,753 |
| RinvoqUpadacitinib | 15 | $100,269 |
| XeljanzTofacitinib Citrate | 11 | $76,660 |
| ForteoTeriparatide | 16 | $66,742 |
| ProliaDenosumab | 32 | $55,407 |
| ActemraTocilizumab | 20 | $42,840 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 11 | $26,221 |
| MethotrexateMethotrexate Sodium | 285 | $6,986 |
| Hydroxychloroquine Sulfate | 129 | $5,073 |
| Mycophenolate Mofetil | 28 | $2,701 |
| Prednisone | 302 | $1,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiKevzara | $1,435 | $150,91033 claims |
| AbbVieRinvoq | $302,009 | $100,26915 claims |
| AmgenProlia, Evenity (2 Syringes) | $8,024 | $81,62843 claims |
| PfizerXeljanz | $12,287 | $76,66011 claims |
| Lilly USA, LLCForteo | $1,004 | $66,74216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Ocoee
- Mariangeli Arroyo AvilaOcoee$1.3M
- Martha Hernandez IllasFort Lauderdale$25M
- Carlos SesinMiami Beach$19M
- Guillermo ValenzuelaPlantation$14.2M
- Marimer Rensoli VelazquezMiami$12.2M
- Robert LevinClearwater$11M
- Jigar ShahMargate$5.6M
- Michael BubbGainesville$3.3M
- Vipul JoshiBrandon$3.1M
- Alvin WellsDestin$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.